The PERK arm of the unfolded protein response (UPR) regulates cellular proteostasis and survival in response to endoplasmic reticulum (ER) stress. However, the impact of PERK signaling on extracellular proteostasis is poorly understood. We define how PERK signaling influences extracellular proteostasis during ER stress using a conformational reporter of the secreted amyloidogenic protein transthyretin (TTR). We show that inhibiting PERK signaling impairs ER stress-dependent secretion of destabilized TTR by increasing its ER retention in chaperone-bound complexes. Interestingly, PERK inhibition promotes the ER stress-dependent secretion of TTR in non-native conformations that accumulate extracellularly as soluble oligomers. Pharmacologic or genetic TTR stabilization partially restores secretion of native TTR tetramers. However, PERK inhibition still increases the ER stress-dependent secretion of TTR in non-native conformations under these conditions, indicating that the conformation of stable secreted proteins can also be affected by inhibiting PERK. Our results define a role for PERK in regulating extracellular proteostasis during ER stress and indicate that genetic or aging-related alterations in PERK signaling can exacerbate ER stress-related imbalances in extracellular proteostasis implicated in diverse diseases.
INTRODUCTION
The PERK signaling arm of the unfolded protein response (UPR) has a critical role in defining cellular survival in response to pathologic insults that disrupt endoplasmic reticulum (ER) proteostasis (i.e., ER stress). PERK is activated in response to ER stress through a mechanism involving PERK dimerization and autophosphorylation [1, 2] . Once activated, PERK phosphorylates the α subunit of eukaryotic initiation factor 2 (eIF2α). This results in both a transient attenuation in new protein synthesis and the activation of stressresponsive transcription factors such as ATF4 [3] [4] [5] . PERK-dependent ATF4 activation induces expression of stress-responsive genes involved in diverse biologic functions including cellular redox, amino acid biosynthesis, and apoptotic signaling [3, 6, 7] . Apart from eIF2α, PERK also has been shown to activate NRF2 to promote cellular redox regulation during ER stress [8, 9] . Through this integration of transcriptional and translational signaling, PERK has a central role in dictating cellular proteostasis and survival in response to varying levels of ER stress. During acute ER insults, PERK signaling is important for regulating protective biologic functions including metabolite homeostasis, cellular redox homeostasis and mitochondrial function [8, [10] [11] [12] . However, chronic PERK activation caused by severe or persistent ER stress promotes apoptotic signaling primarily through the PERK-dependent transcriptional regulation of pro-apoptotic factors [13, 14] .
Consistent with a role for PERK in dictating both protective and pro-apoptotic responses to specific ER insults, imbalances in PERK activity caused by genetic, environmental, or aging-related factors is implicated in the pathogenesis of diverse diseases. Sustained PERK signaling associated with chronic or severe ER insults is implicated in neurodegeneration associated with diseases such as Alzheimer's disease and prion disease, [15, 16] . As such, pharmacologic inhibition of PERK has emerged as a potential strategy to ameliorate neurodegeneration-associated pathologies involved in these disorders [15] . In contrast, genetic and pharmacologic evidence demonstrates that reductions in PERK signaling can also influence disease pathogenesis. Loss-of-function mutations in PERK promote neonatal diabetes in mouse models and the human disease Wolcott-Rallison syndrome [17, 18] . Similarly, hypomorphic PERK alleles are implicated in the tau-associated neurodegenerative disorder progressive supranuclear palsy (PSP), suggesting that reduced PERK signaling promotes toxic tau aggregation [19, 20] . Consistent with this, pharmacologic PERK activation attenuates aggregation and toxicity of PSP-related tau mutants in mouse models [21] . Pharmacologic or chemical genetic increases in PERK signaling also reduce the toxic aggregation of rhodopsin mutants associated with retinal degeneration [19, 22, 23] . Thus, while significant focus has been directed to the pathologic importance of overactive or chronic PERK signaling in disease, it is clear that deficiencies in PERK activity also promote pathogenesis, reflecting a protective role for this UPR signaling arm in regulating cellular physiology in response to ER stress.
Interestingly, recent work has revealed PERK as a critical regulator of proteostasis within the ER -the first organelle of the secretory pathway. PERK-dependent translation attenuation regulates ER protein folding load in response to acute ER stress, freeing ER proteostasis factors to protect the secretory proteome from misfolding during the initial stages of toxic insult [2, 24] . In addition, PERK regulates both ER-to-Golgi anterograde trafficking and ER-associated degradation [25, 26] , the latter a primary mechanism by which cells degrade ER proteins [27] . As such, genetic or pharmacologic inhibition of PERK signaling disrupts secretory proteostasis to reduce the secretion and increase the intracellular accumulation of proteins including collagen, insulin, or rhodopsin in high molecular weight (HMW) aggregates [28] [29] [30] [31] . These results define an important role for PERK in regulating ER proteostasis in response to pathologic insults. However, considering the importance of the ER in regulating proteostasis in downstream secretory environments such as the extracellular space, a critical question remains: ''How does PERK signaling impact extracellular proteostasis in response to ER stress?'.
Imbalances in ER proteostasis can propagate to extracellular environments through the secretion of proteins in non-native conformations that accumulate as toxic oligomers and aggregates associated with proteotoxicity in etiologically-diverse protein aggregation diseases, including many amyloid diseases [32] [33] [34] .
Thus, impaired secretory proteostasis afforded by genetic or aging-related imbalances in PERK activity could exacerbate ER stress-dependent increases in the secretion of non-native proteins, challenging the conformational integrity of the secreted proteome and increasing extracellular populations of toxic oligomers.
Here, we define how pharmacologic inhibition of PERK signaling impacts extracellular proteostasis during ER stress using a conformational reporter of the model secreted amyloidogenic protein transthyretin (TTR) -a natively tetrameric protein that aggregates into toxic oligomers and amyloid fibrils associated with diverse TTRrelated amyloid diseases [35, 36] . We show that blocking PERK activity during ER stress exacerbates the stress-dependent secretion of both destabilized and wild-type TTR in non-native conformations that accumulate extracellularly as soluble oligomers commonly associated with TTR proteotoxicity [35] . These results demonstrate that alterations in PERK signaling can directly challenge extracellular proteostasis by reducing the secretion of native, functional proteins and promoting the extracellular accumulation of soluble oligomers associated with the pathogenesis of diverse types of protein aggregation diseases.
RESULTS & DISCUSSION

PERK inhibition disrupts secretion of destabilized TTR A25T during ER stress
The inhibition of PERK signaling disrupts the trafficking of proteins such as collagen and insulin through the secretory pathway [28] [29] [30] [31] . Here, we define how pharmacologic inhibition of PERK signaling influences secretion of the amyloidogenic protein transthyretin (TTR) during ER stress. Previously, we showed that administration of the ER stressor thapsigargin (Tg) reduces the secretion of destabilized, aggregation-prone TTR variants such as TTR A25T [33, 37, 38] . To define how PERK inhibition influences the Tg-dependent reduction in TTR A25T secretion, we pretreated HEK293T cells expressing FLAG-tagged TTR A25T ( FT TTR A25T ) with Tg and/or the PERK inhibitor ISRIB for 16 h and then monitored FT TTR A25T secretion by [ 35 S] metabolic labeling ( Fig. 1A) . ISRIB is an antagonist of PERK signaling that binds to eIF2B and desensitizes cells to eIF2α phosphorylation [39, 40] . Importantly, co-pretreatment with Tg and ISRIB increased metabolic labeling of FT TTR A25T relative to pretreatment with Tg alone (Fig. 1A,B ). This is consistent with ISRIB blocking Tgdependent translational attenuation downstream of PERK [39, 40] . Interestingly, co-pretreatment with ISRIB and Tg enhanced the Tg-dependent reduction in FT TTR A25T secretion ( Fig. 1A,C ). However, this enhanced reduction in FT TTR A25T secretion did not correspond with an increased loss of total FT TTR A25T , indicating that copretreatment with Tg and ISRIB does not increase FT TTR A25T degradation ( Fig. 1A,D) . Instead, this pretreatment increased the accumulation of FT TTR A25T in lysate fractions, reflecting increased intracellular retention ( Fig. 1A,E) . Identical results were obtained using the PERK inhibitor GSK2656157 (herein referred to as GSK), which blocks PERK signaling by direct binding to the PERK kinase active site ( Fig. EV1A-E) [41] . The use of the two mechanistically distinct inhibitors of PERK signaling indicates that the enhanced reduction in FT TTR A25T secretion observed in cells pretreated with Tg and PERK inhibitors cannot be attributed to offpathway activities of these compounds [42] . Thus, these results show that pharmacologic inhibition of PERK signaling impairs secretory proteostasis for FT TTR A25T during ER stress by reducing its secretion and increasing its intracellular retention.
PERK inhibition increases ER stress-dependent interactions between TTR A25T and ER chaperones.
The intracellular retention of FT TTR A25T observed upon co-pretreatment with Tg and ISRIB likely reflects increased accumulation of non-native TTR conformations within the ER, as observed for other proteins [28, 29, 31] . To test this, we measured the intracellular interaction between FT TTR A25T and ER chaperones, which bind non-native protein conformations, in HEK293T cells treated with Tg and/or ISRIB for 16 h using an established immunopurification (IP)/immunoblotting (IB) assay [38] . Treatment with Tg increases the relative recovery of the ER ATP-dependent HSP70 chaperone BiP and the BiP co-chaperones ERdj3 and HYOU1 in FT TTR A25T IPs ( Fig. 1F and Fig. EV1F ). This indicates that Tg treatment increases the non-native population of intracellular TTR that can engage ER chaperones. Co-treatment with Tg and ISRIB further increased the relative interactions between FT TTR A25T and these ER chaperones, as compared to Tg treatment alone. Importantly, we do not observe significant differences in the intracellular levels of BiP or HYOU1 under these conditions ( Fig.   EV1F ). This indicates that ISRIB-dependent inhibition of PERK signaling does not globally disrupt ER stressdependent upregulation of these UPR target genes. This suggests that disruption of FT TTR A25T secretion afforded by PERK inhibition likely results from translational attenuation, and not impaired transcriptional regulation of these ER chaperones. However, we cannot rule out the possibility that impaired transcription of other UPR-regulated proteins contribute to the altered secretion of FT TTR A25T observed in cells co-treated with Tg and ISRIB. Collectively, these results indicate that the increased accumulation of destabilized FT TTR A25T afforded by co-treatment with PERK inhibitors and ER stress reflects increased ER retention of non-native TTR in chaperone-bound complexes. This suggests that PERK inhibition during ER stress disrupts the ability of cells to properly fold and assemble FT TTR A25T into its native tetrameric conformation.
PERK inhibition reduces the population of FT TTR A25T secreted as native tetramers.
Imbalances in ER proteostasis can propagate to extracellular environments through the secretion of proteins such as TTR in non-native conformations [32, 33] . Thus, we used a previously established assay to define how the ER accumulation of non-native FT TTR A25T observed upon co-treatment with PERK inhibitors and ER stress impacts the conformation of FT TTR A25T secreted from mammalian cells ( Fig. 2A) [33] . In this assay, we collect conditioned media from cells expressing FT TTR A25T prepared in the presence of the cell impermeable compound tafamidis-sulfonate (Taf-S; Fig. EV2A ) -a compound that immediately binds and stabilizes native TTR tetramers once secreted to the extracellular space [33] . We then quantify total, tetrameric, and aggregate TTR in this conditioned media. Total TTR is quantified by SDS-PAGE/IB. Tetrameric TTR is measured by incubating conditioned media with compound 1 (Fig. EV2A ) -a fluorogenic compound that readily displaces the Taf-S in the two small-molecule binding sites of the native TTR tetramer and becomes fluorescent upon binding [33, 43, 44] . Tetramers are then separated by anion exchange chromatography and quantified by compound 1 fluorescence ( Fig. EV2B) . Finally, soluble TTR aggregates are monitored by Clear Native (CN)-PAGE/IB [33, 34] . We previously used this approach to show that Tg-induced ER stress reduces the secretion of destabilized FT TTR A25T as native tetramers and increases accumulation of this destabilized, aggregationprone protein as soluble oligomers in conditioned media [33] .
To define how PERK inhibition influences ER stress-dependent alterations in the conformation of secreted FT TTR A25T , we conditioned media in the presence of Taf-S for 16 h on HEK293T cells expressing FT TTR A25T and treated with Tg and/or ISRIB. We then measured total, tetrameric, and aggregate TTR using the assays described above ( Fig. 2A) . Treatment with Tg reduced the accumulation of total FT TTR A25T in conditioned media, consistent with published results (Fig. 2B) [33, 38] . However, despite pretreatment with Tg and ISRIB reducing the fraction FT TTR A25T secreted (Fig. 1C) , the accumulation of FT TTR A25T in conditioned media over the 16 h incubation was not reduced relative to vehicle-treated cells (Fig. 2B) . This likely reflects the inhibition of PERK-regulated translational attenuation afforded by ISRIB over the duration of the media conditioning ( Fig. 1B) .
We next monitored tetrameric FT TTR A25T in this conditioned media using our compound 1 fluorescence/anion exchange chromatography assay ( Fig. 2A) . As reported previously [33] , FT TTR A25T tetramers in conditioned media migrate as multiple peaks by anion exchange chromatography, reflecting the distribution of heterotetramers consisting of unmodified subunits and subunits containing posttranslational modifications such as sulfonylation and cysteinylation ( Fig. 2C) . Co-treatment with Tg and ISRIB significantly altered the distribution of these peaks, resulting in an increase of heterotetramers eluting earlier on the anion exchange column (Fig. 2C, green) . This suggests that Tg and ISRIB co-treatment alters posttranslational modifications of FT TTR A25T secreted to the extracellular space. As expected, liquid chromatography (LC)-mass spectrometry (MS) analysis of FT TTR A25T IP'd from conditioned media prepared on cells co-treated with Tg and ISRIB shows increased accumulation of unmodified FT TTR A25T (Fig. EV2C) . This is consistent with the earlier migration of tetramers observed under these conditions by anion exchange chromatography and demonstrates that PERK inhibition disrupts the secretory proteostasis environment to influence posttranslational TTR modifications during ER stress.
To quantify the recovery of FT TTR A25T tetramers in conditioned media, we integrated the fluorescence across all of the tetramer peaks. We observed significant reductions in the recovery of FT TTR A25T tetramers in media prepared on Tg-treated cells (Fig. 2B) , consistent with published results [33] . However, despite lower levels of total FT TTR A25T in media conditioned on cells treated with Tg relative to cells treated with Tg and ISRIB, identical amounts of tetramers were detected in conditioned media prepared under these two conditions ( Fig. 2B) . This indicates that PERK inhibition decreases the relative population of FT TTR A25T secreted as native tetramers. This can be demonstrated by normalizing the recovered FT TTR A25T tetramers by the total amount of FT TTR A25T in media prepared on cells treated with Tg and/or ISRIB [33] . This normalization confirms that PERK inhibition reduces the population of FT TTR A25T secreted as native tetramers during ER stress ( Fig. 2D) . Thus, our results show that PERK inhibition increases the ER-stress-dependent secretion of FT TTR A25T in non-native conformations.
Inhibiting PERK increases the extracellular accumulation of FT TTR A25T oligomers during ER stress.
Non-native FT TTR A25T accumulates as soluble oligomers in conditioned media owing to the low stability of the aggregation-prone FT TTR A25T variant [33, 34] . Thus, the increased total secreted TTR ( Fig. 2B) combined with the increased secretion of FT TTR A25T in non-native conformations ( Fig. 2D) in cells co-treated with Tg and ISRIB should be reflected by increased accumulation of extracellular soluble oligomers in media prepared under these conditions. Tg treatment alone significantly increased the accumulation of soluble FT TTR A25T aggregates ( Fig. 2E,F) . This is consistent with previous results and further demonstrates the ER stressdependent increase in the secretion of non-native FT TTR A25T [33] . Interestingly, co-treatment with Tg and ISRIB significantly increased the accumulation of FT TTR A25T soluble aggregates in conditioned media relative to treatment with Tg alone ( Fig. 2E,F) , consistent with the increase in non-native FT TTR A25T secreted under these conditions ( Fig. 2B,D) . These results demonstrate that inhibiting PERK signaling during ER stress directly challenges extracellular proteostasis by exacerbating the ER stress-dependent secretion of destabilized FT TTR A25T in non-native conformations that accumulate extracellularly as soluble oligomers.
Pharmacologic stabilization of TTR tetramers partially rescues the secretion of native FT TTR A25T tetramers in cells treated with PERK inhibitors and ER stress.
TTR tetramers can be stabilized intracellularly by administration of the cell permeable kinetic stabilizer tafamidis (Taf) [33, 37] . Taf-dependent intracellular stabilization prevents the dissociation of tetramers prior to secretion to the extracellular space. Thus, conditioning media in the presence of Taf provides an opportunity to determine whether the increased populations of FT TTR A25T secreted from cells co-treated with Tg and ISRIB reflects increased dissociation of tetramers during the secretion process (i.e., reduced tetramer stability) and/or increased secretion of FT TTR A25T prior to tetramer assembly (i.e., reduced tetramer assembly). To test this, we conditioned media on HEK293T cells expressing FT TTR A25T treated with Tg and/or ISRIB in the presence of either Taf-S or Taf. We then monitored total, tetrameric, and aggregate TTR using the assays shown in Fig.   2A .
Conditioning media in the presence of Taf significantly increased the recovery of FT TTR A25T tetramers in every condition, relative to media conditioned in the presence of Taf-S (Fig. 3A,B and Fig. EV3 ). This indicates that Taf-dependent intracellular stabilization of FT TTR A25T tetramers increases secretion of FT TTR A25T as native tetramers. This increase cannot be attributed to alterations in FT TTR A25T posttranslational modifications, as the addition of Taf does not alter the shift in tetramer distribution observed in cells co-treated with Tg and ISRIB ( Fig. 3B) . Importantly, the increased secretion of FT TTR A25T tetramers corresponds with reductions in the accumulation of soluble FT TTR A25T aggregates in conditioned media (Fig. 3C) . This demonstrates that Tafdependent intracellular stabilization of TTR tetramers reduces the secretion of FT TTR A25T in non-native conformations under all conditions. This indicates that the accumulation of non-native TTR observed under these conditions partially reflects dissociation of TTR tetramers (that can be stabilized intracellularly by Taf) within the secretory pathway. This reveals a specific advantage for employing kinetic stabilizing compound such as Taf that are cell permeable, as these compounds can stabilize aggregation-prone proteins intracellularly and mitigate potential imbalances in secretory proteostasis associated with the aberrant secretion of non-native conformations.
Despite the increased secretion of FT TTR A25T tetramers afforded by Taf-dependent intracellular stabilization, co-administration of Tg and ISRIB in the presence of Taf still increased secretion of FT TTR A25T in non-native conformations, relative to Tg treatment alone (Fig. 3A,D) . Consistent with this, conditioned media prepared on cells co-treated with Tg and ISRIB in the presence of Taf show higher levels of soluble FT TTR A25T oligomers relative to Tg-treated cells, albeit significantly less than that observed for media conditioned in the presence of Taf-S (Fig. 3C) . This demonstrates that despite the ability for Taf to stabilize a large population of FT TTR A25T tetramers in the secretory environment, PERK inhibition can still increase in the secretion of FT TTR A25T in non-native conformations under these conditions.
Secretion of stable, wild-type TTR as native tetramers is reduced in cells co-treated with ER stress and PERK inhibition.
The ability for PERK inhibition to promote ER stress-dependent secretion of FT TTR A25T in non-native conformations even in the presence of the stabilizing ligand Taf suggests that stable, wild-type TTR (TTR WT ) could similarly be susceptible to reductions in tetramer secretion under these conditions. Initially, we confirmed that PERK inhibition disrupts secretory proteostasis for stable FT TTR WT by monitoring the interactions between FT TTR WT and ER chaperones in HEK293T cells treated with Tg and/or the PERK inhibitor GSK. Co-treatment with Tg and GSK significantly increased relative interactions between FT TTR WT and the ER chaperones BiP, ERdj3, and HYOU1 (Fig. 4A) , mimicking the results observed with destabilized FT TTR A25T (Fig. 1F and Fig.   EV1F ). Furthermore, co-treatment with Tg and GSK increased intracellular levels of FT TTR WT , suggesting that this condition leads to intracellular accumulation of stable FT TTR WT (Fig. EV4A) . However, we did not observe significant increases in intracellular levels of BiP or HYOU1, further demonstrating that PERK inhibition does not impact Tg-dependent increases in these chaperones (Fig. EV4A) . Collectively, these results indicate that PERK inhibition during ER stress disrupts secretory proteostasis of stable, wild-type TTR by increasing its ER retention in chaperone-bound complexes -results analogous to that observed for destabilized FT TTR A25T (Fig.   1F and Fig. EV1F ).
Next, we conditioned media in the presence of Taf-S on HEK293T cells expressing FT TTR WT treated with Tg and/or GSK and monitored the recovery of total, tetrameric, or aggregate TTR using the assays described in Fig. 2A . Tg and GSK co-treatment increased the population of FT TTR WT secreted in non-native conformations (Fig. 4B,C and Fig. EV4B) . Identical results were observed in cells co-treated with Tg and ISRIB (Fig. 4D,E) . Normalizing the recovered FT TTR WT tetramers by the total amount of FT TTR WT in conditioned media confirms that PERK inhibition reduces the population of stable FT TTR WT secreted as tetramers during ER stress (Fig. 4F) . Unfortunately, the stability of FT TTR WT monomers (relative to FT TTR A25T monomers) combined with the relatively low concentrations of non-native FT TTR WT in conditioned media hinders the aggregation of this protein in the extracellular space, making it difficult to reproducibly visualize FT TTR WT soluble aggregates in conditioned media [45] . However, co-treatment with Tg and GSK does appear to increase the population of FT TTR WT soluble aggregates observed by CN-PAGE/IB, consistent with the increased secretion of this protein in non-native conformations (Fig. EV4C) . Collectively, these results show that PERK inhibition increases the ER stress-dependent secretion of wild-type TTR in non-native conformations, indicating that PERK inhibition can disrupt extracellular proteostasis of stable secreted proteins.
Concluding Remarks.
Imbalances in PERK signaling are implicated in the onset and pathogenesis of etiologically-diverse diseases [15] [16] [17] [18] [19] [20] [21] [22] [23] . Here, we show that PERK inhibition exacerbates the ER stress-dependent secretion of the disease relevant amyloidogenic protein TTR in non-native conformations that accumulate extracellularly as soluble oligomers commonly associated with TTR proteotoxicity [35] . This indicates that PERK signaling has an important role in dictating extracellular proteostasis by controlling the conformational integrity of secreted proteins. As such, genetic, aging-related, or pharmacologic conditions that reduce PERK signaling can lead to pathologic imbalances in extracellular proteostasis that contributes to human disease. The increased secretion of proteins in non-native conformations will increase extracellular populations available for concentrationdependent aggregation into toxic oligomers and amyloid fibrils, as we show for TTR. Alternatively, reduced secretion of proteins in native conformations can also prevent important functions of secreted proteins in biologic activities such as hormonal signaling, cell-cell communication and immunological signaling. Thus, our demonstration that reduction in PERK activity can impact the conformation of secreted proteins such as TTR reveals a new mechanism that can contribute to the pathogenesis of diseases associated with genetic or aging-related reductions in PERK activity. Furthermore, our results reveal a new consideration when employing PERK inhibitors to attenuate chronic PERK activation in disease, as this approach can promote imbalances in extracellular proteostasis and function that could be detrimental for long-term organismal survival
MATERIALS AND METHODS
Plasmids, Antibodies and Reagents
The FT TTR A25T and FT TTR WT plasmids were prepared in the pcDNAI vector as previously reported [38] . were transfected with FT TTR A25T / FT TTR WT in pcDNAI using calcium phosphate transfection, as previously reported [38] . Cells were incubated in transfection media overnight and media was replaced with fresh supplemented complete media the next morning. Cells were lysed with 20 mM HEPES pH 7.2, 100 mM NaCl, 1% Triton X, 1 mM EDTA unless otherwise stated. Cell lysates were normalized to over all protein concentration in each sample using a Bradford assay.
[ 35 S] metabolic labeling assay
Metabolic labeling assays were performed as previously described [37, 38] . Briefly, HEK293T cells transfected with FT TTR A25T pretreated for 16 h with the indicated condition were labeled for 30 min with EasyTag Express 35 S Protein Labeling Mix (0.1mCi/mL; Perkin Elmer) in DMEM lacking both Cys and Met (Invtrogen) supplemented with 10% dialyzed FBS, penicillin/streptomycin, and glutamine. Cells were then washed and incubated in complete media. At the indicated time, media and lysates were collected. FT TTR A25T was then immunopurified from the lysate and media using anti-Flag M1 Agarose Affinity Gel (Sigma Aldrich) and incubated overnight. We then washed the beads and eluted FT TTR A25T by boiling the beads in 3x Laemmli buffer including 100 mM DTT. Proteins were separated on a 12% SDs-PAGE gel, dried, exposed to phosphorimager plates (GE Healthcare), and imaged with a Typhoon imager. Band intensities were quantified by densitometry using ImageQuant. Fraction secreted was calculated using the equation: fraction secreted = 
Media Conditioning, SDS-PAGE, CN-PAGE and Immunoblotting
HEK293T cells transfected with FT TTR A25T / FT TTR WT were incubated overnight. The following morning media was changed and cells were incubated for 1 hour. Cells were then replated into a poly-D-lysine coated 6-well plate. The next evening, cells were treated with the indicated treatment for 16 hours and conditioned in 1 mL of media. Conditioned media was then collected and cleared from large debris by centrifugation at 1000 x g for 10 min. For SDS-PAGE, samples were boiled in Lammeli Buffer containing 100 mM DTT for 5 minutes and resolved on a 12% acrylamide gel. Gels were transferred to 0.2 µm nitrocellulose membranes at 100V for 60 minutes. For CN-PAGE, samples were added to 5x Clear Native Page Buffer (final concentration: 0.1% Ponceau Red, 10% glycerol, 50mM 6-aminohexanoic acid, 10mM Bis-Tris pH 7.0) and resolved at 4°C on a Novex NativePage 4-16% Bis-Tris Protein Gel run at 150 V for 3 hours. Protein was transferred at 100 V for 90 minutes to a 0.2 µm nitrocellulose membrane. Membranes were incubated with the indicated primary antibody overnight and then incubated with the appropriate LICOR secondary antibody. Protein bands where then visualized and quantified using the LICOR Odyssey Infrared Imaging System.
Quantification of FT TTR tetramers in conditioned media
FT TTR tetramers in conditioned media were quantified as previously described [33] . Briefly, conditioned media was prepared on HEK293T cells expressing the indicated FT TTR variant treated with the indicated conditions. Conditioned media was then incubated with 5 µM compound 1 overnight. Media samples (60 µL) were separated over a Waters Protein-Pak Hi Res Q, 5 µm 4.6 x 100 mm anion exchange column in 25 mm Tris pH 8.0, 1 mM EDTA with a linear 1M NaCl gradient using a ACQUITY UPLC H-Class Bio System (Waters).
Fluorescence of TTR tetramers conjugated to compound 1 was observed by excitation at 328 nm and emission at 430 nm. Peaks were integrated and data was collected using Empower 3 software according to the manufacture's protocol.
Liquid chromatography (LC)-mass spectrometry of immunopurified FT TTR
Media was conditioned for 18 h on HEK293T cells transfected with FT TTR A25T treated with the indicated condition. Media was then collected and cleared from debris by centrifugation at 1000 x for 10 min. FT TTR A25T was immunopurified from the conditioned media using anti-Flag M1 Agarose gel. Beads were than washed 3x with 10 mM Tris pH 8.0 100 mM NaCL containing 0.05% saponin and 2x with 10 mM Tris pH 8.0 100 mM NaCL without saponin. FT TTR A25T was eluted at 4 degrees C overnight with 50 µL of 0.1 M triethylamine dissolved in water pH 11.5 with gentle shaking. Eluted TTR molecular weights were analyzed by LC-MS, as previously described [33] .
Statistical Methods
All p-values were calculated using a paired student's t-test. FT TTR WT tetramers were separated on anion exchange chromatography using the UPLC system and visualized by compound 1 fluorescence. F. Graph showing normalized FT TTR WT tetramers in conditioned media prepared in the presence of Taf-S on HEK293T cells treated for 16 h with Tg (500 nM), ISRIB (200 nM), and/or GSK (300 nM). Normalized TTR tetramers were calculated using the formula: normalized TTR tetramers for a given condition = (TTR tetramer signal condition / TTR tetramer signal veh) / (total TTR signal condition / TTR tetramer signal veh). Error bars show SEM for n=10. *p<0.05; p<0.01; p<0.005 for two-tailed paired t-test.
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